CDSCO approved recombinant live attenuated dengue vaccine for age group 4 to 60 years
GK and monthly revision
CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
India's Central Drugs Standard Control Organization (CDSCO) has approved a recombinant live attenuated dengue vaccine for use in individuals aged 4 to 60 years. The approval follows comprehensive scientific evaluation of the vaccine's quality, safety, and efficacy by the Union Health Ministry. This marks a significant milestone in India's public health strategy against dengue, a major vector-borne disease endemic across the country. The vaccine's broad age range enhances its potential for mass immunization programs and strengthens India's indigenous vaccine development capabilities.
Source: The Hindu. This summary and analysis are AI-written from that report and are not individually fact-checked — confirm names, dates and figures with the source before you rely on them.
Revision structure
Monthly events and exam calendar context
Static GK and one-liner notes
Quiz and mock-test revision path
Key points
Exam-ready takeaways
Approval granted after comprehensive scientific evaluation of quality, safety, and efficacy
Decision announced by Union Health Ministry
Vaccine targets dengue, a major vector-borne disease endemic in India
Significant step for India's indigenous vaccine development and public health immunization strategy
How to study
Turn news into exam marks
Revise monthly events by exam family instead of reading random updates.
Pair one-liners with mock tests so mistakes become the next revision list.
Note which exams each story matters for, and revise it again in the week before that exam.